ACADL

Overview

ACADL (Acyl-CoA Dehydrogenase Long Chain) encodes a mitochondrial enzyme involved in fatty acid beta-oxidation. In the cancer genomics corpus it has been identified as an IHC-validated proteomic marker distinguishing molecular group 1 (MG1) meningiomas, where high ACADL protein expression marks the benign, NF2-driven meningioma subgroup.

Alterations observed in the corpus

  • ACADL protein expression validated by immunohistochemistry as a marker for MG1 (NF2-mutant, benign) meningiomas in an integrative molecular classification study (n=201 meningiomas; 121 discovery, 80 validation) PMID:34433969.

Cancer types (linked)

  • MNG — ACADL IHC positivity identifies MG1 meningiomas, the most favorable prognostic group in the four-class integrative molecular classification PMID:34433969.

Co-occurrence and mutual exclusivity

  • MG1 meningiomas with high ACADL expression are characterized by near-universal NF2 mutations/chromosome 22q loss (88%) and are NF2-wild type-marker negative (TRAF7, AKT1, KLF4, SMO) PMID:34433969.

Therapeutic relevance

  • No direct therapeutic targeting of ACADL is reported. Its utility is as a diagnostic/prognostic IHC marker to assign molecular group in standard neuropathology laboratories PMID:34433969.

Open questions

  • Independent validation of ACADL IHC as a single-marker MG1 classifier in unselected meningioma populations is needed PMID:34433969.

Sources

This page was processed by crosslinker on 2026-04-11.